Graft Polymer (UK) Plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders.
Here is an excellent interview with new Chairman Dennis Purcell. This guy has done it all in Biotech, worth a quick watch.
Looking a bit better. Maybe found a bottom. Really is worth having a listen to Dennis Purcel above on that video, people like him don’t often get involved with micro caps on AIM.
Dennis Biog
I can’t find on FT or are you asking for it to be added ?
A chat thread about the share… but would be good if they added it too!
Can Admins change this to SVNS - Solvonis Therapeutics plc? They changed name a few months ago.
Have a read .. fully funded- and look up Dennis Purcell. Serial winner in this game. Back the right people.
——
With a mission to tackle the global crisis of addiction and mental health disorders, this company is backed by an elite leadership team, a game-changing product pipeline, and a fast-track pathway to the U.S. market.
At the core of Solvonis’s vision is SVN-002, a revolutionary treatment for moderate to severe alcohol use disorder. This isn’t just another pill — it’s a novel oral thin film delivery of esketamine, combined with structured psycho-social support. The innovation here is twofold: a proprietary drug delivery system that enhances absorption and effect, and a dual-therapy approach designed to maximise real-world patient outcomes.
The FDA has already given its nod of approval in a positive pre-IND meeting, supporting the use of the efficient 505(b)(2) regulatory pathway — meaning this product could hit the market faster and with less cost than traditional drug development routes.
Alcohol use disorder affects over 14 million adults in the U.S. alone, with limited treatment options and a high relapse rate. SVN-002 offers a completely new approach — one that could completely disrupt the current treatment model.
What truly sets Solvonis apart is its leadership. Prof. David Nutt, the company’s Chief Scientific Advisor, is a global authority on neuropsychopharmacology, regularly seen on TV and widely respected across academic and clinical circles. With over 500 research papers and 36 books to his name, his involvement adds instant credibility — and more importantly, visionary insight.
Then there’s Dennis Purcell, Chairman of Solvonis (LON:SVNS) and a titan of the biotech industry. Having led over $15 billion in deals, Purcell knows how to scale high-potential biotech businesses into billion-dollar winners. He’s made it clear: Solvonis is targeting some of the most pressing medical needs of our time — PTSD, depression, addiction — and they have the technology to deliver real change. He believes the company’s drug delivery and polymer modification platform will be key to driving major partnerships with pharma and biotech giants.
Solvonis Therapeutics (LON:SVNS) is making headlines for all the right reasons — and their flagship addiction treatment, SVN-001, could soon become one of the most important breakthroughs in mental health.
With the potential to transform the lives of millions battling alcohol use disorder, this revolutionary program is now in fully funded Phase III trials — the final step before potential market approval — and the data so far is nothing short of astonishing.
SVN-001 isn’t just another treatment — it’s redefining what success looks like in addiction recovery.
In Phase II trials, patients entered the program averaging just 2% sobriety — roughly seven sober days a year. After treatment, that number rocketed to 86% sobriety at six months post-treatment. That’s not incremental improvement — that’s life-changing transformation.
Even more remarkable is how efficiently Solvonis is executing. The Phase III trial is being conducted in partnership with the UK Department of Health, supported by NHS addiction specialists, and being run at a cost of just £800,000 — a figure virtually unheard of in the biopharma world. With national health backing, this isn’t just a trial — it’s a potential blueprint for the UK’s future in addiction care.
Behind the science is a world-class leadership team. Professor David Nutt, one of the most recognised names in neuropsychopharmacology, is guiding the scientific direction. With over 500 publications and decades of groundbreaking work, his involvement adds serious credibility.
Meanwhile, Chairman Dennis Purcell, who has overseen over $15 billion in biotech deals, sees SVN-001 as a cornerstone of Solvonis’s broader mission to revolutionise mental health treatment.
With Phase III now underway, national recognition, and clinical data that rivals anything in the sector, Solvonis Therapeutics is quickly becoming a serious contender in the mental health space. And with a tiny market cap and growing investor interest, the stock could be poised for explosive upside as awareness builds.
This is more than just a clinical trial — it’s a defining moment in the battle against addiction. And for investors who understand the power of real-world impact backed by science, Solvonis could be a rare early-stage opportunity with massive future potential.
still getting a lot of interest. I mean I’m not an expert by any means, but a treatment for alcohol addiction, backed by the NHS in final stage trial - where people in stage 2 trial went from 2% staying sober before treatment to 86% after treatment got to be something
